Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium–glucose cotransporter 2 inhibitor

Fig. 1

Enrollment of patients with type 2 diabetes mellitus (T2DM) treated with sodium–glucose cotransporter 2 inhibitors (SGLT2i). In total, 10,237 patients with T2DM without prevalent AF treated with SGLT2i were enrolled from June 1, 2016, to December 31, 2018. AF: atrial fibrillation; SGLT2i: sodium–glucose cotransporter 2 inhibitor; T2DM: type 2 diabetes mellitus

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840